{"id":52990,"date":"2026-03-18T11:13:50","date_gmt":"2026-03-18T05:43:50","guid":{"rendered":"https:\/\/newstrackbhopal.com\/index.php\/2026\/03\/18\/cliniexperts-supports-successful-completion-of-the-amplify-tir-diabetes-study-in-india\/"},"modified":"2026-03-18T11:13:50","modified_gmt":"2026-03-18T05:43:50","slug":"cliniexperts-supports-successful-completion-of-the-amplify-tir-diabetes-study-in-india","status":"publish","type":"post","link":"https:\/\/newstrackbhopal.com\/index.php\/2026\/03\/18\/cliniexperts-supports-successful-completion-of-the-amplify-tir-diabetes-study-in-india\/","title":{"rendered":"CliniExperts Supports Successful Completion of the AMPLIFY-TIR Diabetes Study in India"},"content":{"rendered":"<p dir=\"ltr\"><em>CliniExperts Supports Successful Completion of the AMPLIFY-TIR Diabetes Study in India<\/em><\/p>\n<p dir=\"ltr\"><span data-sheets-root=\"1\"><strong>New Delhi [India], March 18:<\/strong> <\/span>We are pleased to announce the successful completion of the AMPLIFY-TIR Study, which evaluated fixed-dose combinations (FDCs) of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors in Indian patients with type 2 diabetes mellitus (T2DM) using continuous glucose monitoring (CGM).<\/p>\n<p dir=\"ltr\">This prospective, randomised, open-label, triple-arm clinical study conducted across six centres in India included 90 adults with T2DM on stable metformin therapy who were randomised to receive teneligliptin + dapagliflozin, sitagliptin + dapagliflozin, or linagliptin + empagliflozin.\u00a0CliniExperts Research\u00a0served as the Indian arm Contract Research Organization (CRO) for this study, supporting the clinical research activities across participating sites.<\/p>\n<p dir=\"ltr\">The study demonstrated meaningful improvements in glycaemic stability and variability parameters, with a favourable safety profile and no new safety concerns. Through this work, we aim to highlight the clinical utility of SGLT2i + DPP-4i fixed-dose combinations for improving glycaemic control in Indian patients with T2DM.<\/p>\n<p dir=\"ltr\">Website Link:\u00a0<a href=\"https:\/\/cliniexperts-research.com\/news\/amplify-tir-study\/\" target=\"_blank\" rel=\"noopener\">https:\/\/cliniexperts-research.com\/news\/amplify-tir-study<\/a><\/p>\n<p dir=\"ltr\"><em>If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CliniExperts Supports Successful Completion of the AMPLIFY-TIR Diabetes Study in India New Delhi [India], March 18: We are pleased to announce the successful completion of the AMPLIFY-TIR Study, which evaluated fixed-dose combinations (FDCs) of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors in Indian patients with type 2 diabetes mellitus (T2DM) using continuous glucose [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":52989,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[56,11],"tags":[2374,2375],"class_list":["post-52990","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-press-release","tag-amplify-tir","tag-cliniexperts"],"wpmagazine_modules_lite_featured_media_urls":{"thumbnail":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2026\/03\/NW-SRV-150x150.jpg",150,150,true],"cvmm-medium":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2026\/03\/NW-SRV-300x300.jpg",300,300,true],"cvmm-medium-plus":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2026\/03\/NW-SRV-305x207.jpg",305,207,true],"cvmm-portrait":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2026\/03\/NW-SRV-400x600.jpg",400,600,true],"cvmm-medium-square":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2026\/03\/NW-SRV-600x600.jpg",600,600,true],"cvmm-large":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2026\/03\/NW-SRV-1024x675.jpg",1024,675,true],"cvmm-small":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2026\/03\/NW-SRV-130x95.jpg",130,95,true],"full":["https:\/\/newstrackbhopal.com\/wp-content\/uploads\/2026\/03\/NW-SRV.jpg",1200,675,false]},"categories_names":{"56":{"name":"Health","link":"https:\/\/newstrackbhopal.com\/index.php\/category\/health\/"},"11":{"name":"Press Release","link":"https:\/\/newstrackbhopal.com\/index.php\/category\/press-release\/"}},"tags_names":{"2374":{"name":"AMPLIFY-TIR","link":"https:\/\/newstrackbhopal.com\/index.php\/tag\/amplify-tir\/"},"2375":{"name":"CliniExperts","link":"https:\/\/newstrackbhopal.com\/index.php\/tag\/cliniexperts\/"}},"comments_number":"0","_links":{"self":[{"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/posts\/52990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/comments?post=52990"}],"version-history":[{"count":0,"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/posts\/52990\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/media\/52989"}],"wp:attachment":[{"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/media?parent=52990"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/categories?post=52990"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newstrackbhopal.com\/index.php\/wp-json\/wp\/v2\/tags?post=52990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}